Interstitial Cystitis - Pipeline Insight, 2025

DelveInsight’s, “Interstitial Cystitis - Pipeline Insight, 2025,” report provides comprehensive insights about 8+ companies and 10+ pipeline drugs in Interstitial Cystitis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Interstitial Cystitis Understanding

Interstitial Cystitis: Overview

Interstitial cystitis (IC), also called bladder pain syndrome, is a chronic, or long-lasting, condition that causes painful urinary symptoms. Symptoms of IC may be different from person to person. For example, some people feel mild discomfort, pressure, or tenderness in the pelvic area. Other people may have intense pain in the bladder or struggle with urinary urgency, the sudden need to urinate, or frequency, the need to urinate more often. IC can occur at any age, including during childhood, but is most common in adult women and men. About twice as many women are affected as men.1 However, more men may struggle with IC than researchers originally thought. Some research suggests that women are more likely to develop IC if they have a history of being sexually abused or physically traumatized

""Interstitial Cystitis - Pipeline Insight, 2025"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Interstitial Cystitis pipeline landscape is provided which includes the disease overview and Interstitial Cystitis treatment guidelines. The assessment part of the report embraces, in depth Interstitial Cystitis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Interstitial Cystitis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Interstitial Cystitis R&D. The therapies under development are focused on novel approaches to treat/improve Interstitial Cystitis.

Interstitial Cystitis Emerging Drugs Chapters

This segment of the Interstitial Cystitis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Interstitial Cystitis Emerging Drugs

• Certolizumab pegol: UCB

Certolizumab pegol (Cimzia) developed by UCB, Belgium is a recombinant, humanized F(ab)’ fragment of an antibody conjugated to polyethylene glycol to enhance its plasma half-life. It is in phase 3 stage of development for the treatment of Interstitial cystitis.

• SI-722: Seikagaku Corporation

SI-722 is a novel chemical compound in which a steroid is conjugated with chondroitin sulfate using Seikagaku's proprietary glycosaminoglycan modification technology and drug delivery systems (DDS). SI-722 injected into the bladder is thought to demonstrate long-lasting improvement in the conditions of frequent urination and bladder pain by releasing a steroid with an anti-inflammatory effect. SI-722 has completed a Phase I clinical study in the U.S. In November 2019, it is starting a Phase I/II clinical study. This clinical study will evaluate the drug for safety, tolerability, and pharamcokinetics, and will conduct an exploratory evaluation of its effectiveness.

Further product details are provided in the report……..

Interstitial Cystitis: Therapeutic Assessment

This segment of the report provides insights about the different Interstitial Cystitis drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players in Interstitial Cystitis

There are approx. 8+ key companies which are developing the therapies for Interstitial Cystitis. The companies which have their Interstitial Cystitis drug candidates in the most advanced stage, i.e. phase III include, UCB.

• Phases

DelveInsight’s report covers around 10+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Interstitial Cystitis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical.
• Molecule Type

Products have been categorized under various Molecule types such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Interstitial Cystitis: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Interstitial Cystitis therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Interstitial Cystitis drugs.

Interstitial Cystitis Report Insights

• Interstitial Cystitis Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Interstitial Cystitis Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Interstitial Cystitis drugs?
• How many Interstitial Cystitis drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Interstitial Cystitis?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Interstitial Cystitis therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Interstitial Cystitis and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Merck & Co
• Teva Pharmaceutical Industries
• Integrative Therapeutics, Inc.
• Lipella Pharmaceuticals, Inc.
• Addex Therapeutics
• Seikagaku Corporation
• UCB
• Alivio Therapeutics
• Imbrium Therapeutics
• Ironwood Pharmaceuticals

Key Products

• IW 3300
• LYT 503
• Fremanezumab
• IMB-115
• Research programme: GABAB PAM
• SI-722
• Certolizumab

Show more